FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043303586> ?p ?o ?g. }

• W2043303586 endingPage "1348" @default.
• W2043303586 startingPage "1332" @default.
• W2043303586 abstract "Although fractionation can be used in a discrete radiobiologic sense, herein it is generally used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies. Fractionation is a strategy for overcoming heterogeneity of monoclonal antibody (MAb) distribution in the tumor and the consequent nonuniformity of tumor radiation doses. Additional advantages of fractionated RIT are the ability to 1) provide patient-specific radionuclide and radiation dosing, 2) control toxicity by titration of the individual patient, 3) reduce toxicity, 4) increase the maximum tolerated dose (MTD) for many patients, 5) increase tumor radiation dose and efficacy, and 6) prolong tumor response by permitting treatment over time. However, fractionated RIT has logistic and economic implications. Preclinical and clinical data substantiate the advantages of fractionated RIT, although the radiobiology for conventional external beam radiotherapy does not provide a straightforward rationale for RIT unless fractionation leads to more uniform distribution of radiation dose throughout the tumor. Preclinical data have shown that toxicity and mortality can be reduced while efficacy is increased, thereby providing inferential evidence of greater uniformity of radiation dose. Direct evidence of superior dosimetry and tumor activity distribution has also been found. Clinical data have shown that toxicity can be better controlled and reduced and the MTD extended for many patients. It is clear that fractionated RIT can only fulfill its potential if the effects of critical issues, such as the number and amount of radionuclide doses, the radionuclide physical and effective half-life, and the dose interval, are better characterized. Cancer 2002;94:1332–48. © 2002 American Cancer Society. DOI 10.1002/cncr.10304" @default.
• W2043303586 created "2016-06-24" @default.
• W2043303586 creator A5038808449 @default.
• W2043303586 creator A5039475847 @default.
• W2043303586 creator A5044505402 @default.
• W2043303586 creator A5050136149 @default.
• W2043303586 creator A5052212062 @default.
• W2043303586 creator A5078161354 @default.
• W2043303586 creator A5084679942 @default.
• W2043303586 creator A5091194020 @default.
• W2043303586 date "2002-02-12" @default.
• W2043303586 modified "2023-10-17" @default.
• W2043303586 title "Rationales, evidence, and design considerations for fractionated radioimmunotherapy" @default.
• W2043303586 cites W1869307723 @default.
• W2043303586 cites W1943037631 @default.
• W2043303586 cites W1955500944 @default.
• W2043303586 cites W1966454446 @default.
• W2043303586 cites W1966827463 @default.
• W2043303586 cites W1973372786 @default.
• W2043303586 cites W1976526493 @default.
• W2043303586 cites W1976871572 @default.
• W2043303586 cites W1983915199 @default.
• W2043303586 cites W1984893522 @default.
• W2043303586 cites W1986478975 @default.
• W2043303586 cites W1992689348 @default.
• W2043303586 cites W1993546257 @default.
• W2043303586 cites W1994358730 @default.
• W2043303586 cites W2003757234 @default.
• W2043303586 cites W2008118429 @default.
• W2043303586 cites W2011447425 @default.
• W2043303586 cites W2011843181 @default.
• W2043303586 cites W2016794176 @default.
• W2043303586 cites W2020378886 @default.
• W2043303586 cites W2027223027 @default.
• W2043303586 cites W2029517266 @default.
• W2043303586 cites W2033787072 @default.
• W2043303586 cites W2034608909 @default.
• W2043303586 cites W2035409077 @default.
• W2043303586 cites W2037401464 @default.
• W2043303586 cites W2041682834 @default.
• W2043303586 cites W2048254406 @default.
• W2043303586 cites W2048807047 @default.
• W2043303586 cites W2058136787 @default.
• W2043303586 cites W2060769059 @default.
• W2043303586 cites W2066610908 @default.
• W2043303586 cites W2076531398 @default.
• W2043303586 cites W2079397728 @default.
• W2043303586 cites W2080456673 @default.
• W2043303586 cites W2080833363 @default.
• W2043303586 cites W2083437069 @default.
• W2043303586 cites W2084377890 @default.
• W2043303586 cites W2084697597 @default.
• W2043303586 cites W2086205241 @default.
• W2043303586 cites W2089181511 @default.
• W2043303586 cites W2105150213 @default.
• W2043303586 cites W2106363471 @default.
• W2043303586 cites W2106816194 @default.
• W2043303586 cites W2128997140 @default.
• W2043303586 cites W2137197268 @default.
• W2043303586 cites W2149612540 @default.
• W2043303586 cites W2151415400 @default.
• W2043303586 cites W2166406736 @default.
• W2043303586 cites W2320751441 @default.
• W2043303586 cites W2332464142 @default.
• W2043303586 cites W2476478265 @default.
• W2043303586 cites W4233562436 @default.
• W2043303586 cites W4246970675 @default.
• W2043303586 cites W4296766361 @default.
• W2043303586 doi "https://doi.org/10.1002/cncr.10304" @default.
• W2043303586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11877764" @default.
• W2043303586 hasPublicationYear "2002" @default.
• W2043303586 type Work @default.
• W2043303586 sameAs 2043303586 @default.
• W2043303586 citedByCount "119" @default.
• W2043303586 countsByYear W20433035862012 @default.
• W2043303586 countsByYear W20433035862013 @default.
• W2043303586 countsByYear W20433035862014 @default.
• W2043303586 countsByYear W20433035862015 @default.
• W2043303586 countsByYear W20433035862016 @default.
• W2043303586 countsByYear W20433035862017 @default.
• W2043303586 countsByYear W20433035862018 @default.
• W2043303586 countsByYear W20433035862019 @default.
• W2043303586 countsByYear W20433035862021 @default.
• W2043303586 countsByYear W20433035862022 @default.
• W2043303586 countsByYear W20433035862023 @default.
• W2043303586 crossrefType "journal-article" @default.
• W2043303586 hasAuthorship W2043303586A5038808449 @default.
• W2043303586 hasAuthorship W2043303586A5039475847 @default.
• W2043303586 hasAuthorship W2043303586A5044505402 @default.
• W2043303586 hasAuthorship W2043303586A5050136149 @default.
• W2043303586 hasAuthorship W2043303586A5052212062 @default.
• W2043303586 hasAuthorship W2043303586A5078161354 @default.
• W2043303586 hasAuthorship W2043303586A5084679942 @default.
• W2043303586 hasAuthorship W2043303586A5091194020 @default.
• W2043303586 hasBestOaLocation W20433035861 @default.
• W2043303586 hasConcept C125118446 @default.
• W2043303586 hasConcept C126322002 @default.
• W2043303586 hasConcept C151730666 @default.

• next